Lv2
145 积分 2020-11-01 加入
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
1个月前
已完结
High-risk MCL: recognition and treatment
1个月前
已完结
Treatment approaches for patients with TP53-mutated mantle cell lymphoma
1个月前
已完结
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm
1个月前
已完结
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm
1个月前
已关闭
Best in Class? DLBclass, a New Classification Tool for Diffuse Large B-Cell Lymphoma to Facilitate Development of Molecular-Based Precision Treatments
5个月前
已关闭
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma
5个月前
已完结
DLBCL: who is high risk and how should treatment be optimized?
5个月前
已完结
High-risk MCL: recognition and treatment
6个月前
已完结
皖公网安备34019202002308
